|Awarded On||December 05, 2012|
|Title||Investigating PI3K inhibition-mediated feedback regulation in renal cancer treatment|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Boyi Gan|
|Cancer Sites||Kidney and Renal Pelvis, Other|
How to choose the most effective targeted cancer therapy strategy for individual cancer patient is an important and challenging issue. Single-agent therapy usually targets one particular molecule or pathway; however, such therapy often activates other cancer signaling pathways, resulting in drug resistance over time. A more effective therapy may therefore require a combination of agents to inhibit the other cancer signaling pathways that are activated by a particular drug. However, combination therapies generally involve problems with toxicity. Also, only a fraction of cancer patients typically benefit from combination therapies, which means many other patients who receive these therapies do...